ANVISA Accelerated Approval: Two-Year Impact on Breakthrough Cancer Therapies

Key Takeaways

• No accelerated pathway: ANVISA does not offer a breakthrough therapy designation equivalent to the FDA's program established under FDASIA Section 902 in 2012.
• 522-day median delay: Research published in PubMed documents that oncology drug approvals in Brazil lag FDA approvals by a median of 522 days.
• Faster with survival data: ANVISA prioritizes drugs demonstrating overall survival (OS) benefits and those supported by randomized controlled trials.
• EMA advantage: The EMA's PRIME scheme provides accelerated assessment that ANVISA does not match.
• Market impact: Extended timelines may discourage smaller biotech firms from entering Brazil, limiting patient access to innovative therapies.

How Does ANVISA's Oncology Framework Differ from the FDA?

ANVISA regulates cancer drugs through a standard marketing authorization process. This differs from the tiered system the FDA employs.

The FDA established breakthrough therapy designation through FDASIA Section 902 in July 2012. A drug qualifies when early clinical data shows substantial improvement over existing treatments. The FDA reviews requests within 60 days.

ANVISA does not maintain an equivalent pathway. According to ANVISA's official guidance, marketing authorization reviews take 365 days for ordinary applications and 120 days for priority review drugs. These timelines apply uniformly across therapeutic areas without specialized oncology expedited tracks.

The gap matters. Companies can secure FDA breakthrough status early. They gain rolling submissions, priority review, and FDA guidance. ANVISA offers none of these for cancer drugs.

What Drives Faster ANVISA Approvals?

Certain drug characteristics accelerate ANVISA reviews within the standard framework. Understanding these factors helps sponsors optimize submission timing.

Randomized controlled trial (RCT) data speeds approvals. Drugs supported by RCTs receive faster decisions than those relying on single-arm studies or observational evidence. ANVISA emphasizes strong clinical evidence. The agency applies the same rigor across all therapeutic categories.

Overall survival (OS) benefit also accelerates review. The FDA calls OS the gold standard endpoint in oncology trials. ANVISA follows similar principles. Drugs showing OS gains move faster than those with only response rate or progression-free survival (PFS) data.

Priority review designation helps. ANVISA grants priority status to drugs addressing unmet needs. However, even priority reviews follow the 120-day statutory timeline. No mechanism exists for the rolling submissions or accelerated approval available through FDA pathways.

How Long Is the FDA-ANVISA Approval Gap?

Quantifying the delay requires examining actual approval dates. Academic research provides concrete figures.

A study in PubMed on immune checkpoint inhibitors for lung cancer found ANVISA-FDA disagreements on only 20% of approvals. However, timing diverged. The research showed major delays between FDA clearance and Brazilian authorization.

The median gap stands at 522 days. This figure, cited in regulatory analyses, represents the additional time Brazilian patients wait for therapies available in the United States. For aggressive cancers, this delay spans treatment windows that determine outcomes.

Consider pembrolizumab (Keytruda). FDA granted initial approval for advanced melanoma on September 4, 2014. The agency has since approved dozens of additional indications across lung cancer, bladder cancer, and other malignancies. Brazilian patients typically access each new indication more than a year after U.S. availability.

What About the EMA Alternative?

European regulatory mechanisms highlight what ANVISA lacks. The European Medicines Agency (EMA) offers structured acceleration that Brazil has not replicated.

The PRIME (Priority Medicines) scheme provides early and proactive support to developers. Benefits include:

• Early appointment of rapporteurs one month after eligibility
• Kick-off meetings with multidisciplinary expert groups
• Dedicated PRIME scientific coordinator
• Expedited scientific advice at key milestones
• Submission readiness meetings approximately one year before marketing authorization

PRIME builds on existing accelerated assessment tools. Developers expect eligibility for accelerated assessment at marketing authorization application. This compresses review timelines meaningfully.

ANVISA offers no equivalent scheme. Brazilian oncology sponsors navigate standard procedures without early engagement, iterative scientific advice, or submission readiness support. The gap in regulatory infrastructure contributes to the 522-day median delay.

Which Factors Shape Market Entry Strategy?

The approval delay reshapes pharmaceutical company decisions on Brazilian market entry. Strategic implications vary by company size and portfolio.

Large pharmaceutical companies absorb extended timelines more readily. Diversified portfolios generate revenue during ANVISA review periods. Established infrastructure in Brazil handles regulatory submissions and post-approval activities. These firms can wait 522 days without existential risk.

Smaller biotechnology companies face different calculus. Many depend on rapid revenue generation to fund operations. A 522-day delay before first Brazilian sales strains cash reserves. Some conclude that market entry costs exceed projected returns. They prioritize regions with faster pathways.

Competitive dynamics shift during the delay window. First movers in Brazil establish market share before late entrants complete ANVISA review. By the time a delayed therapy launches, competitors may dominate prescribing patterns. Reimbursement negotiations become harder without competitive pressure.

Regional harmonization could help. If Brazil, Mexico, Argentina, and other LATAM markets aligned on accelerated pathways, the region would attract more investment. Fragmented rules currently force sponsors to navigate distinct national procedures. This compounds timeline challenges.

Could ANVISA Add Accelerated Pathways?

Regulatory modernization remains possible. ANVISA could adopt mechanisms modeled on FDA or EMA frameworks.

Implementation would require investment. Specialized oncology review divisions need staffing. Rolling submission procedures demand IT infrastructure and process redesign. Training programs must prepare reviewers for accelerated timelines.

Stakeholder engagement matters. Pharmaceutical companies, Brazilian oncology societies, and patient advocacy groups can demonstrate demand for faster access. The PubMed research on checkpoint inhibitors identified improvement in ANVISA's time performance following the 2008 prioritization review. Further gains may follow continued advocacy.

Harmonization offers longer-term promise. If multiple Latin American regulators adopted aligned accelerated pathways, sponsors could pursue simultaneous regional submissions. This would compress total time-to-market across LATAM. ANVISA participation in such harmonization would benefit Brazilian patients substantially.

Frequently Asked Questions

Related Coverage

Explore our analysis of biosimilar approval pathways across ANVISA and COFEPRIS for additional LATAM regulatory context. For a case study in successful Brazilian oncology approvals, see our coverage of Enhertu's HER2-positive breast cancer authorization. Investors tracking regulatory impacts on market entry should review our cancer treatment market analysis.

Primary Sources

1. ANVISA. "Medicinal Products." Brazilian Health Regulatory Agency, updated April 2024. — Official ANVISA guidance on marketing authorization timelines and procedures.
2. FDA. "Fact Sheet: Breakthrough Therapies." U.S. Food and Drug Administration, March 2018. — FDASIA Section 902 breakthrough therapy designation criteria.
3. EMA. "PRIME: Priority Medicines." European Medicines Agency, October 2015. — PRIME scheme features and eligibility.
4. FDA. "Keytruda (pembrolizumab) Approval History." Drugs@FDA, accessed 2024. — FDA approval dates and supplement history for pembrolizumab.
5. de Oliveira et al. "Immune checkpoint inhibitors for the treatment of non-small cell lung cancer: The regulatory journey in Brazil." PubMed, 2023. — Academic analysis of ANVISA-FDA approval delays for ICIs in NSCLC.
6. FDA. "Approaches to Assessment of Overall Survival in Oncology Clinical Trials: Guidance for Industry." August 2025. — FDA guidance on OS as primary endpoint in oncology.
7. FDA. "Oncologic Drugs Advisory Committee Meeting Briefing Document." November 2023. — Accelerated approval verification timelines and median time to confirmatory trial completion.